Le Lézard
Classified in: Health
Subjects: TRI, PSF, FVT

Emerald Lake Safety Presenting Multiple Posters at September 23-25 ACCP Meetings in Maryland


NEWPORT BEACH, Calif., Aug. 30, 2018 /PRNewswire/ -- Emerald Lake Safety ("ELS"), an independent group researching ways to reduce the dangerous side effects associated with prescription pharmaceuticals, will present three posters on Sept. 23-25 at the 2018 American College of Clinical Pharmacology (ACCP) meetings in Bethesda, Maryland.

The Posters will address newly discovered and clinically validated drug-drug interactions and drug-disease interactions and what doctors need to do to avoid them. 

"We are proud to be sharing these important safety findings with other researchers and medical professionals," said Sundar Srinivasan, Chief Executive Officer and founder of Emerald Lake Safety. "These discoveries are the fruit of a broad clinical research program ELS is conducting to reduce Serious Adverse Events associated with pharmaceutical use. In addition to these posters, ELS' clinical work has led to the publication of five peer-reviewed articles in 2018." 

ELS said that in some cases, participating doctors will receive continuing education credits through ACCP's CME and CPE programs.

Srinivasan said ELS' mission is to pursue high quality clinical and genomic research that can clearly establish potential sources of Serious Adverse Events arising from the use of marketed pharmaceuticals. 

"Generally multi-million dollar projects, robust clinical trials like these are beyond the scope of most independent investigators. Yet they are necessary to secure regulatory support for changes in how a drug is used," he said. "Such changes mean fewer adverse events, allowing doctors to deliver more benefit with less risk."

According to a recent analysis by Yale researchers, of the 222 drugs approved in a 10-year cohort between 2001 and 2010, 123 (55%) had major post-marketing safety events, resulting in three withdrawals, 61 black box warnings and 59 FDA-issued safety communications.

For more information about ELS visit www.emeraldlakesafety.com.

Press Contact:
Brandon Fremd
[email protected]
(657) 204-6942

SOURCE Emerald Lake Safety


These press releases may also interest you

at 03:03
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark. With the solution, they aim to elevate the educational...

at 03:00
Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).  ...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...



News published on and distributed by: